Castle Biosciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Castle Biosciences şirketinin toplam hissedar öz sermayesi $441.1M ve toplam borcu $10.0M olup, bu da borç-öz sermaye oranını 2.3% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $514.6M ve $73.5M dir.

Anahtar bilgiler

2.3%

Borç/özkaynak oranı

US$10.02m

Borç

Faiz karşılama oranı	n/a
Nakit	US$279.79m
Eşitlik	US$441.06m
Toplam yükümlülükler	US$73.51m
Toplam varlıklar	US$514.57m

Son finansal sağlık güncellemeleri

Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment?

Jul 12

Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans

Oct 31

Recent updates

Are Investors Undervaluing Castle Biosciences, Inc. (NASDAQ:CSTL) By 49%?

Oct 15

Castle Biosciences: Inflection Into Profitability

Aug 16

Upgrade: Analysts Just Made A Meaningful Increase To Their Castle Biosciences, Inc. (NASDAQ:CSTL) Forecasts

Aug 11

Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Aug 08

Castle Biosciences, Inc.'s (NASDAQ:CSTL) 28% Share Price Surge Not Quite Adding Up

Aug 04

Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment?

Jul 12

Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark

Apr 30

Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects

Jan 27

Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans

Oct 31

Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive

Jun 13

Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL)

Aug 14

Castle Biosciences Q2 2022 Earnings Preview

Aug 08

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CSTL 'nin kısa vadeli varlıkları ( $344.8M ) kısa vadeli yükümlülüklerini ( $44.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: CSTL şirketinin kısa vadeli varlıkları ( $344.8M ) uzun vadeli yükümlülüklerini ( $29.2M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CSTL şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: CSTL 'nin borç/öz sermaye oranı son 5 yılda 30.2% seviyesinden 2.3% seviyesine düştü.

Borç Kapsamı: CSTL 'nin borcu işletme nakit akışı ( 590% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: CSTL şirketinin borçlarına ilişkin faiz ödemelerinin EBIT tarafından iyi bir şekilde karşılanıp karşılanmadığını belirlemek için yeterli veri yok.

Castle Biosciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment?

Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans

Recent updates

Castle Biosciences, Inc. Announces the Latest Data from Its Prospective, Multicenter Decide Study Exploring the Impact of Integrating Decisiondx-Melanoma Test Results into SLNB Decision-Making for Patients Recently Diagnosed with Melanoma

Castle Biosciences, Inc. Increases Earnings Guidance for the Year 2024

Are Investors Undervaluing Castle Biosciences, Inc. (NASDAQ:CSTL) By 49%?

Castle Biosciences, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Castle Biosciences to Present New Data on Decisiondx-Melanoma and Decisiondx-Um At 21St International Congress of the Society for Melanoma Research

Castle Biosciences, Inc.s’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma

Castle Biosciences, Inc. Announces the Publication of New Study in Future Oncology

Castle Biosciences: Inflection Into Profitability

Upgrade: Analysts Just Made A Meaningful Increase To Their Castle Biosciences, Inc. (NASDAQ:CSTL) Forecasts

Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Castle Biosciences, Inc. Revises Financial Guidance for the Full Year 2024

Castle Biosciences, Inc.'s (NASDAQ:CSTL) 28% Share Price Surge Not Quite Adding Up

Castle Biosciences, Inc. to Report Q2, 2024 Results on Aug 05, 2024

Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment?

Castle Biosciences, Inc. Announces that AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher Test

Castle Biosciences, Inc. Announces That New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis

Castle Biosciences, Inc. Announces to Present New Data Related to Its DecisionDx-Melanoma and DecisionDx-UM Tests At the 2024 American Society of Clinical Oncology

Castle Biosciences, Inc. Announces New Data from A Study Further Confirming the Performance of its DecisionDx-UM Test as A Robust Independent Predictor of Metastasis-Free Survival (MFS) in Patients Diagnosed with UM

Consensus estimates of losses per share improve by 28%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Castle Biosciences, Inc. Revises Earnings Guidance for the Full Year of 2024

Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark

Founder notifies of intention to sell stock

Castle Biosciences, Inc. to Report Q1, 2024 Results on May 02, 2024

Castle Biosciences, Inc., Annual General Meeting, May 23, 2024

Independent Chairman of the Board notifies of intention to sell stock

Castle Biosciences, Inc. Announces Share New Data At the 20Th European Association of Dermato-Oncology Congress

Castle Biosciences, Inc. Announces Board Changes

Castle Biosciences, Inc. Announces the Publication of a New Multi-Center Performance Study of its DecisionDx-SCC Risk Stratification Test

Founder notifies of intention to sell stock

Consensus estimates of losses per share improve by 26%

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Castle Biosciences, Inc. Provides Revenue Guidance for the Full Year 2024

Castle Biosciences, Inc. to Report Second Half, 2023 Results on Feb 28, 2024

Independent Chairman of the Board notifies of intention to sell stock

Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects

Castle Biosciences, Inc. Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii

Castle Biosciences, Inc. Provides Revenue Guidance for the Year 2023

Forecast to breakeven in 2026

Founder exercised options and sold US$362k worth of stock

Independent Chairman of the Board notifies of intention to sell stock

Founder notifies of intention to sell stock

Castle Biosciences, Inc. Announces Data from A Single-Site, Open-Label Study Demonstrating the Consistent Impact of Idgenetix®? on Medication Response and Remission Rates in Patients with Major Depressive Disorder

Consensus estimates of losses per share improve by 21%

Castle Biosciences, Inc. Announces New Data Showing the Ability of Its Pipeline Test in Development to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Castle Biosciences, Inc. Raises Earnings Guidance for the Full Year 2023

Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans

Castle Biosciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Castle Biosciences, Inc. Announces New Study Demonstrating DecisionDx-Melanoma Outperforms a Nomogram Developed at the Memorial Sloan Kettering Cancer Center

Castle Biosciences, Inc. Shares New Data Demonstrating Ability of TissueCypher Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett's Esophagus

Castle Biosciences, Inc. Announces TissueCypher Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus

Castle Biosciences, Inc. Announces Data from a Study Showing the Addition of Drug-Drug Interactions and Lifestyle Factors to Drug-Gene Interactions

Consensus estimates of losses per share improve by 12%

Founder notifies of intention to sell stock

Castle Biosciences, Inc. Raises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Independent Chairman of the Board notifies of intention to sell stock

Castle Biosciences to Present New DecisionDx®-Melanoma Data at the American Head & Neck Society's 11th International Conference on Head and Neck Cancer

Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive

Castle Biosciences, Inc. Presents New Data Demonstrating the Ability of DecisionDx-SCC to Identify Tumors Likely to Metastasize in Patients with Cutaneous Squamous Cell Carcinoma Deemed Low Risk by Traditional Staging

Independent Director recently bought US$69k worth of stock

Price target decreased by 11% to US$39.75

Castle Biosciences, Inc. to Share New Data on DecisionDx-Melanoma and DecisionDx-UM at the 2023 ASCO Annual Meeting

Consensus EPS estimates fall by 16%, revenue upgraded

Founder notifies of intention to sell stock

Castle Biosciences, Inc. Reaffirms Revenue Guidance for the Full Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 11%, revenue upgraded

Full year 2022 earnings: EPS exceeds analyst expectations

Castle Biosciences, Inc. Publishes Data from Prospective, Multicenter Study, Called DECIDE